Clinical Trial Update: Ocrelizumab for Psychosis by Autoimmunity [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating ocrelizumab as a treatment for autoimmune-related psychosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Schizo-Affective Type of Psychosis, Schizophrenia | Phase 1, Phase 2 | Status: RECRUITING